Scientific Reports (Feb 2021)

An arylthiazyne derivative is a potent inhibitor of lipid peroxidation and ferroptosis providing neuroprotection in vitro and in vivo

  • Meike Hedwig Keuters,
  • Velta Keksa-Goldsteine,
  • Hiramani Dhungana,
  • Mikko T. Huuskonen,
  • Yuriy Pomeshchik,
  • Ekaterina Savchenko,
  • Paula K. Korhonen,
  • Yajuvinder Singh,
  • Sara Wojciechowski,
  • Šárka Lehtonen,
  • Katja M. Kanninen,
  • Tarja Malm,
  • Jouni Sirviö,
  • Anu Muona,
  • Milla Koistinaho,
  • Gundars Goldsteins,
  • Jari Koistinaho

DOI
https://doi.org/10.1038/s41598-021-81741-3
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Lipid peroxidation-initiated ferroptosis is an iron-dependent mechanism of programmed cell death taking place in neurological diseases. Here we show that a condensed benzo[b]thiazine derivative small molecule with an arylthiazine backbone (ADA-409-052) inhibits tert-Butyl hydroperoxide (TBHP)-induced lipid peroxidation (LP) and protects against ferroptotic cell death triggered by glutathione (GSH) depletion or glutathione peroxidase 4 (GPx4) inhibition in neuronal cell lines. In addition, ADA-409-052 suppresses pro-inflammatory activation of BV2 microglia and protects N2a neuronal cells from cell death induced by pro-inflammatory RAW 264.7 macrophages. Moreover, ADA-409-052 efficiently reduces infarct volume, edema and expression of pro-inflammatory genes in a mouse model of thromboembolic stroke. Targeting ferroptosis may be a promising therapeutic strategy in neurological diseases involving severe neuronal death and neuroinflammation.